Results 101 to 110 of about 453,081 (334)

Impact of Elevated Preprocedural Left Ventricular Filling Pressure on Prognosis of Mild Paravalvular Regurgitation Following Transcatheter Aortic Valve Replacement

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Paravalvular regurgitation (PVR) following transcatheter aortic valve replacement (TAVR) is a complication linked to poor outcomes. The prognostic impact of mild PVR, particularly in patients with elevated preprocedural left ventricular (LV) filling pressure, remains uncertain.
Shumpei Kosugi, Isamu Mizote, Daisuke Nakamura, Hiroki Sugae, Yutaka Matsuhiro, Shota Okuno, Ai Kawamura, Kizuku Yamashita, Koichi Maeda, Kazuo Shimamura, Tomoharu Dohi, Yasuharu Takeda, Yasushi Sakata   +12 more
wiley   +1 more source

The Diagnostic Values of Protein to Lactate Dehyrogenase Ratio in Serum and Pleural Fluid in Exudate Pleural Effusions [PDF]

Journal of Cardio-Thoracic Medicine, 2013
Introduction: Different etiologies of pleural effusion are diagnosed based on serum and plural fluid characteristics. The aim of this study was to assess and compare the serum and pleural fluid protein to lactate dehyrogenase (Pr/LDH) ratio in exudative ...
Zahra Hadizadeh Talasaz, Shahrzad M.Lari, Reza Basiri, Mohammad Towhidi, Davood Attaran, Amir Asnaashari, Zahra Javid-Arabshahi   +6 more
doaj  

Paclitaxel‐Coated Balloons for Femoropopliteal Artery Disease Treatment in French Patients: A Longitudinal Observational Study

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Clinical studies have demonstrated the safety and effectiveness of drug‐coated balloon (DCB) angioplasty for femoropopliteal revascularization. Long‐term studies in routine practice are limited. Aims The aim of this study was to assess long‐term outcomes after DCB angioplasty for femoropopliteal peripheral artery disease in a real ...
Yann Gouëffic, Maxime Dubosq‐Lebaz, Jean‐François Heautot, Aurore Tricotel, Antoine Sauguet   +4 more
wiley   +1 more source

COPD: Optimizing Treatment [PDF]

, 2015
A guideline update and an expanded armamentarium have many physicians wondering how best to treat patients with COPD. Chronic obstructive pulmonary disease (COPD) carries a high disease burden. In 2012, it was the 4th leading cause of death worldwide.1,2
Ahmed-Sarwar, Nabila, Holub, David C, Pierce, Deirdre P   +2 more
core   +1 more source

The validity of using ICD-9 codes and pharmacy records to identify patients with chronic obstructive pulmonary disease [PDF]

, 2011
Background: Administrative data is often used to identify patients with chronic obstructive pulmonary disease (COPD), yet the validity of this approach is unclear.
AA Ginde, AD Lopez, AHRQ quality indicators, AS Buist, AS Gershon, AS Gershon, BG Druss, BR Celli, BR Celli, C Macie, CL Tsai, Colin R Cooke, David H Au, DD Sin, DW Mapel, DW Mapel, E Jung, Edmunds M Udris, Eric Johnson, EW Steyerberg, FT Shaya, FT Shaya, G Clermont, GR Washko, H Akaike, J McKnight, JD Maclay, JL Hankinson, JV Tu, JW Peabody, KF Rabe, KR Chapman, LM Lix, Min J Joo, MK Han, MP Swanney, MR Miller, National Committee for Quality Assurance (NCQA), NS Rawson, PG Camp, RJ Halbert, RJ Halbert, S Kesten, SD Sullivan, SE Bleeker, Stephen M Anderson, T Parimon, TA Lee, TA Lee, Todd A Lee, VS Fan, VS Fan, Y Lacasse   +52 more
core   +5 more sources

Treatment With Phosphodiesterase 5 Inhibitors and Long‐Term Outcomes in Patients Undergoing Coronary Angiography and Cardiac Catheterization

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background The effects of phosphodiesterase 5 (PDE5) inhibitors on the incidence of long‐term outcomes in patients with cardiovascular disease are not well understood. Objective: We studied the association between PDE5 inhibitor therapy and the incidence of adverse cardiovascular major adverse cardiovascular events (MACE) in patients ...
Sumon Roy, Annette Min, Edward O. McFalls, Robert A. Perera, Fadi N. Salloum, Ion S. Jovin   +5 more
wiley   +1 more source

Occupation and COPD [PDF]

Occupational and Environmental Medicine, 2005
Time for action Chronic obstructive pulmonary disease (COPD) is now the fourth leading cause of death worldwide and, by all reasonable projections, its incidence will increase. The worldwide burden of COPD morbidity and mortality is already large, and will become staggering in this century.
openaire   +2 more sources

Risk factors for acute exacerbations of COPD in a primary care population: A retrospective observational cohort study [PDF]

, 2014
Objectives: To evaluate risk factors associated with exacerbation frequency in primary care. Information on exacerbations of chronic obstructive pulmonary disease (COPD) has mainly been generated by secondary care-based clinical cohorts.
Hawkins, A, Müllerová, H, Quint, J, Shukla, A   +3 more
core   +3 more sources

Long‐Term Follow‐Up After Direct‐Flow Transcatheter Aortic Valve Implantation: A Single Center Experience

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Aims Valve degeneration after DirectFlow implantation poses a challenge for valve‐in‐valve procedures due to its fragile polymeric structure and embolization risk. This study analyzes long‐term follow‐up of patients who underwent TAVI with DF to understand valve degeneration tendencies.
Dan M. Prunea, Raffael Geissler, Alexandru Achim, Cosima Stark, Sadeek S. Kanoun Schnur, Brigitte Strobl, Heiko Bugger, Olev Luha, Birgit Zirngast, Albrecht Schmidt, Andreas Zirlik, Gabor G. Toth   +11 more
wiley   +1 more source

Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.
Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu, Zhenbang Gu, Wengen Zhu, Shenghui Feng   +3 more
wiley   +1 more source